MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 154 filers reported holding MERSANA THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $346,716 | -66.5% | 273,005 | -13.2% | 0.00% | – |
| Q2 2023 | $1,034,649 | +357.8% | 314,483 | +841.1% | 0.00% | – |
| Q3 2022 | $226,000 | -67.6% | 33,416 | -80.9% | 0.00% | – |
| Q1 2022 | $698,000 | +6.6% | 175,021 | +66.0% | 0.00% | – |
| Q4 2021 | $655,000 | -29.0% | 105,423 | +7.8% | 0.00% | – |
| Q3 2021 | $922,000 | +29.5% | 97,832 | +86.8% | 0.00% | – |
| Q2 2021 | $712,000 | -30.5% | 52,372 | -17.3% | 0.00% | -100.0% |
| Q1 2021 | $1,025,000 | -87.8% | 63,335 | -79.9% | 0.00% | -75.0% |
| Q4 2020 | $8,404,000 | +636.5% | 315,820 | +415.7% | 0.00% | – |
| Q3 2020 | $1,141,000 | -72.1% | 61,243 | -65.0% | 0.00% | -100.0% |
| Q2 2020 | $4,090,000 | +5580.6% | 174,778 | +1310.5% | 0.00% | – |
| Q1 2020 | $72,000 | -71.1% | 12,391 | -79.8% | 0.00% | – |
| Q2 2019 | $249,000 | +315.0% | 61,459 | +441.7% | 0.00% | – |
| Q1 2019 | $60,000 | – | 11,346 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $40,026,000 | 4.69% |
| Opaleye Management Inc. | 1,047,000 | $4,837,000 | 2.18% |
| Sarissa Capital Management LP | 4,299,297 | $19,863,000 | 2.00% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $4,178,000 | 1.58% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 850,000 | $3,927,000 | 1.21% |
| Orbimed Advisors | 9,011,437 | $41,633,000 | 0.75% |
| Avoro Capital Advisors LLC | 7,550,000 | $34,881,000 | 0.69% |
| Rock Springs Capital Management LP | 4,075,958 | $18,831,000 | 0.55% |
| Artal Group S.A. | 2,200,000 | $10,164,000 | 0.54% |
| DAFNA Capital Management LLC | 406,763 | $1,879,000 | 0.51% |